<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03649750</url>
  </required_header>
  <id_info>
    <org_study_id>2013-MUC-01</org_study_id>
    <nct_id>NCT03649750</nct_id>
  </id_info>
  <brief_title>Mucinex® ER 600 mg Bi-Layer Tablet Fed and Fasted</brief_title>
  <official_title>A Phase I, Open-label, Single-dose, Randomized, 2-way Cross-over Study Designed to Examine the Relative Bioavailability of Guaifenesin When a Mucinex Extended Release 600 mg Bi-layer Tablet is Taken Under Fasted Compared to Fed Conditions in Normal Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reckitt Benckiser LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reckitt Benckiser LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine and compare the plasma concentrations of Mucinex® Extended Release (ER) 600 mg
      bi-layer tablet in normal healthy volunteers in fed and fasting conditions
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 29, 2013</start_date>
  <completion_date type="Actual">August 7, 2013</completion_date>
  <primary_completion_date type="Actual">August 7, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Guaifenesin</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)</time_frame>
    <description>Maximum measured analyte concentration over the sampling period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Plasma Concentration-time Curve From Time 0 to the Last Measurable Plasma Concentration (AUCt) of Guaifenesin</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)</time_frame>
    <description>The area under the analyte concentration versus time curve, from time zero (0) to the time of the last measurable analyte concentration (t), as calculated by the linear trapezoidal method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax) of Guaifenesin</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)</time_frame>
    <description>Time of the maximum measured analyte concentration over the sampling period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) of Guaifenesin</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)</time_frame>
    <description>The area under the analyte concentration versus time curve from time zero to infinity.
AUCinf = AUCt + Cp/Kel,
where Cp is the predicted analyte concentration at the time of the last measurable analyte concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Rate Constant (Kel) of Guaifenesin</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)</time_frame>
    <description>Elimination rate constant calculated from the slope of the terminal portion of the plasma profile calculated by least-squares regression of log (concentration) versus time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-life (T½) of Guaifenesin</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)</time_frame>
    <description>Terminal elimination half-life, calculated from the equation: thalf = In(2)/Kel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Bioavailability (RF) of Guaifenesin</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)</time_frame>
    <description>Relative bioavailability for each formulation will be defined as:
(AUC0-inf Fasting ÷ AUC0-inf Fed) x (Fed dose ÷ Fasting dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events(AEs) Experienced by Participants</measure>
    <time_frame>Up to period 2 (8.3 days/200 hours)</time_frame>
    <description>Intensity determination Mild=AE does not limit usual activities;subject may experience slight discomfort Moderate=AE results in some limitation of usual activities;subject may experience significant discomfort Severe=AE results in an inability to carry out usual activities;subject may experience intolerable discomfort or pain Unassessable/Unclassifiable=Insufficient information to be able to make an assessment Conditional/Unclassified=Insufficient information to make an assessment at present(causality is conditional on additional information) Unrelated=No possibility that the AE was caused by study drug Unlikely=Slight but remote chance that the AE was caused by study drug but the balance of judgment is that it was most likely not due to the study drug Possible=Reasonable suspicion that the AE was caused by the study drug Probable=Most likely that the AE was caused by study drug Certain=The AE was definitely caused by study drug</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Treatment A: Mucinex® 600 mg (fast)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mucinex® 600 mg ER bi-layer tablet by mouth after 10 hours fasting and subject will fast at least 4 hours post-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: Mucinex® 600 mg (fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mucinex® 600 mg ER bi-layer tablet by mouth in fed condition. After an overnight fast of at least 10 hours, subjects will consume a high fat, high calorie breakfast starting 30 minutes prior to drug administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mucinex®</intervention_name>
    <description>Mucinex® 600 mg ER bi-layer tablets</description>
    <arm_group_label>Treatment A: Mucinex® 600 mg (fast)</arm_group_label>
    <arm_group_label>Treatment B: Mucinex® 600 mg (fed)</arm_group_label>
    <other_name>guaifenesin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent was obtained (i.e. be informed of the nature of the study and given
             written consent prior to any study procedure). Able to read, understand, and sign the
             informed consent, after the nature of the study had been explained.

          2. Age: 18 to 55 years of age, inclusive.

          3. Sex: male or female.

          4. Status: Healthy subjects.

          5. BMI: ≥18.0 and ≤28.0 kg/m2.

          6. No clinically significant findings in vital signs measurements at screening.

          7. No clinically significant abnormal laboratory values at screening.

          8. No clinically significant findings from a 12-lead electrocardiogram (ECG) at
             screening.

          9. Had no significant diseases or clinically relevant medical condition in the opinion of
             the Investigator

         10. Males who participated in this study were willing to:

               -  remain abstinent [not engage in sexual intercourse] from the start of drug
                  administration until 90 days after the end of the study or

               -  used (or their partner used, as applicable) two effective methods of birth
                  control [condom, diaphragm, cervical cap, vaginal sponge, spermicide, IUD, tubal
                  ligation, vasectomy, or hormonal contraceptives] from the start of drug
                  administration until 90 days after the end of the study.

             Females who participated in this study were:

               -  unable to have children (e.g., post-menopausal, hysterectomy);

               -  willing to remain abstinent [not engage in sexual intercourse] from 21 days prior
                  to drug administration until 30 days after the end of the study; or

               -  willing to use two effective methods of birth control [condom, diaphragm,
                  cervical cap, vaginal sponge, spermicide, non-hormonal Intrauterine Device (IUD)
                  (in place for 3 months), tubal ligation, partner has vasectomy, hormonal
                  contraceptives for 3 months prior to drug administration] from 30 days prior to
                  drug administration until 30 days after the end of the study.

         11. Had no clinically significant findings from a physical examination.

        Exclusion Criteria:

          1. Employee of Pharma Medica Research Inc. (PMRI) or Reckitt Benckiser.

          2. Partner or first-degree relative of any Investigator at PMRI.

          3. Known history or presence of any clinically significant medical condition.

          4. Known or suspected carcinoma.

          5. Presence of hepatic or renal dysfunction.

          6. Presence of clinically significant gastrointestinal disease or history of
             malabsorption within the year preceding the study.

          7. Known history or presence of galactose or fructose intolerance, sucrase-isomaltase
             insufficiency, Lapp lactase insufficiency, galactosemia, or glucose-galactose
             malabsorption syndrome.

          8. Presence of a medical condition requiring regular medication (prescription and/or
             over-the-counter) with systemic absorption.

          9. History of drug or alcohol or medicinal product addiction requiring treatment within
             the two years preceding the study or excessive alcohol consumption (more than 10 units
             per week)

             Note: one unit is defined as 5 ounces of wine, 12 ounces of beer, or 1.5 ounces of
             spirits.

         10. Positive test result for serum Human Chorionic Gonadotropin (hCG) consistent with
             pregnancy (females only), HIV, Hepatitis B surface antigen or Hepatitis C antibody.

         11. Positive test result for urine drugs of abuse (cannabinoids, opiates, amphetamines,
             cocaine, phencyclidine, tricyclic antidepressants, barbiturates, methadone and
             benzodiazepines) or urine cotinine.

         12. Difficulty fasting or consuming standard meals.

         13. Females who were lactating.

         14. Did not tolerate venipuncture.

         15. Use of tobacco or nicotine-containing products within 12 months prior to drug
             administration.

         16. On a special diet within 30 days prior to drug administration (e.g., liquid, protein,
             raw food diet).

         17. Donation or loss of whole blood (including clinical trials):

               -  ≥50 ml and ≤499 ml within 30 days prior to drug administration

               -  ≥500 ml within 56 days prior to drug administration

         18. Females who had started taking hormonal contraceptives or had changed their method or
             brand of hormonal birth control within 3 months prior to drug administration.

         19. Had a tattoo or body piercing within 30 days prior to drug administration.

         20. Use of drugs of the monoamine oxidase inhibitor (MAOI) class within 30 days prior to
             drug administration.

         21. Known history or presence of hypersensitivity, intolerance or idiosyncratic reaction
             to guaifenesin or any other drug substances with similar activity.

         22. Previously enrolled in this study.

         23. Participated in another clinical trial or received an investigational product within
             30 days prior to drug administration.

         24. Unable in the opinion of the Investigator to comply fully with the study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2018</study_first_posted>
  <results_first_submitted>October 8, 2018</results_first_submitted>
  <results_first_submitted_qc>October 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 22, 2019</results_first_posted>
  <last_update_submitted>March 18, 2019</last_update_submitted>
  <last_update_submitted_qc>March 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guaifenesin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a single-centre study.</recruitment_details>
      <pre_assignment_details>Total Thirty-six (36) subjects were enrolled in the study among them 36 subjects completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1(Mucinex Fed or Mucinex Fast in Period 1 and Period 2)</title>
          <description>Treatment A (Test): Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under overnight fasting.
Treatment B (Test): Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under high calorie breakfast fed.
Cohort 1
Period 1 - Treatment A or Treatment B at Sequence AB.
Period 2 - Treatment B or Treatment A at Sequence BA.
Scheduled Washout of 7 days between drug doses.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2(Mucinex Fast or Mucinex Fed in Period 1 and Period 2)</title>
          <description>Treatment A (Test): Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under overnight fasting.
Treatment B (Test): Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under high calorie breakfast fed.
Cohort 2
Period 1 - Treatment A or Treatment B at Sequence AB.
Period 2 - Treatment B or Treatment A at Sequence BA.
Scheduled Washout of 7 days between drug doses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout: 7 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Pharmacokinetic (PK) Dataset Subjects from whom the observation/estimation of Cmax and AUC measures/parameters were possible for two periods were included in the PK dataset.</population>
      <group_list>
        <group group_id="B1">
          <title>Pharmacokinetic (PK) Dataset</title>
          <description>Treatment A (Test): Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under overnight fasting.
Treatment B (Test): Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under high calorie breakfast fed.
Cohort 1
Period 1 - Treatment A or Treatment B at Sequence AB.
Period 2 - Treatment B or Treatment A at Sequence BA.
Scheduled Washout of 7 days between drug doses.
Cohort 2
Period 1 - Treatment A or Treatment B at Sequence AB.
Period 2 - Treatment B or Treatment A at Sequence BA.
Scheduled Washout of 7 days between drug doses.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.8" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.3" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.7" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 - 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>41 - 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of Guaifenesin</title>
        <description>Maximum measured analyte concentration over the sampling period.</description>
        <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)</time_frame>
        <population>Pharmacokinetic (PK) Dataset are the Subjects from whom the observation/estimation of Cmax and AUC measures/parameters will be possible for two periods will be included in the PK dataset.
The PK dataset will be defined prior to the assay of samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Mucinex® 600 mg (Fast)</title>
            <description>Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under overnight fasting.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: Mucinex® 600 mg (Fed)</title>
            <description>Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under high calorie breakfast fed.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of Guaifenesin</title>
          <description>Maximum measured analyte concentration over the sampling period.</description>
          <population>Pharmacokinetic (PK) Dataset are the Subjects from whom the observation/estimation of Cmax and AUC measures/parameters will be possible for two periods will be included in the PK dataset.
The PK dataset will be defined prior to the assay of samples.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1066.11" spread="429.91"/>
                    <measurement group_id="O2" value="1117.31" spread="424.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under Plasma Concentration-time Curve From Time 0 to the Last Measurable Plasma Concentration (AUCt) of Guaifenesin</title>
        <description>The area under the analyte concentration versus time curve, from time zero (0) to the time of the last measurable analyte concentration (t), as calculated by the linear trapezoidal method.</description>
        <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)</time_frame>
        <population>Pharmacokinetic Dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Mucinex® 600 mg (Fast)</title>
            <description>Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under overnight fasting.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: Mucinex® 600 mg (Fed)</title>
            <description>Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under high calorie breakfast fed.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Plasma Concentration-time Curve From Time 0 to the Last Measurable Plasma Concentration (AUCt) of Guaifenesin</title>
          <description>The area under the analyte concentration versus time curve, from time zero (0) to the time of the last measurable analyte concentration (t), as calculated by the linear trapezoidal method.</description>
          <population>Pharmacokinetic Dataset</population>
          <units>ng·h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4052.10" spread="1495.48"/>
                    <measurement group_id="O2" value="4084.90" spread="1380.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Observed Plasma Concentration (Tmax) of Guaifenesin</title>
        <description>Time of the maximum measured analyte concentration over the sampling period.</description>
        <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)</time_frame>
        <population>Pharmacokinetic Dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Mucinex® 600 mg (Fast)</title>
            <description>Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under overnight fasting.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: Mucinex® 600 mg (Fed)</title>
            <description>Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under high calorie breakfast fed.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Plasma Concentration (Tmax) of Guaifenesin</title>
          <description>Time of the maximum measured analyte concentration over the sampling period.</description>
          <population>Pharmacokinetic Dataset</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.32"/>
                    <measurement group_id="O2" value="3.33" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) of Guaifenesin</title>
        <description>The area under the analyte concentration versus time curve from time zero to infinity.
AUCinf = AUCt + Cp/Kel,
where Cp is the predicted analyte concentration at the time of the last measurable analyte concentration.</description>
        <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)</time_frame>
        <population>Pharmacokinetic Dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Mucinex® 600 mg (Fast)</title>
            <description>Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under overnight fasting.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: Mucinex® 600 mg (Fed)</title>
            <description>Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under high calorie breakfast fed.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) of Guaifenesin</title>
          <description>The area under the analyte concentration versus time curve from time zero to infinity.
AUCinf = AUCt + Cp/Kel,
where Cp is the predicted analyte concentration at the time of the last measurable analyte concentration.</description>
          <population>Pharmacokinetic Dataset</population>
          <units>ng·h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4104.47" spread="1555.87"/>
                    <measurement group_id="O2" value="4092.53" spread="1382.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Rate Constant (Kel) of Guaifenesin</title>
        <description>Elimination rate constant calculated from the slope of the terminal portion of the plasma profile calculated by least-squares regression of log (concentration) versus time.</description>
        <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)</time_frame>
        <population>Pharmacokinetic Dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Mucinex® 600 mg (Fast)</title>
            <description>Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under overnight fasting.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: Mucinex® 600 mg (Fed)</title>
            <description>Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under high calorie breakfast fed.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Rate Constant (Kel) of Guaifenesin</title>
          <description>Elimination rate constant calculated from the slope of the terminal portion of the plasma profile calculated by least-squares regression of log (concentration) versus time.</description>
          <population>Pharmacokinetic Dataset</population>
          <units>1/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3862" spread="0.1717"/>
                    <measurement group_id="O2" value="0.6788" spread="0.1343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-life (T½) of Guaifenesin</title>
        <description>Terminal elimination half-life, calculated from the equation: thalf = In(2)/Kel.</description>
        <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)</time_frame>
        <population>Pharmacokinetic Dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Mucinex® 600 mg (Fast)</title>
            <description>Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under overnight fasting.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: Mucinex® 600 mg (Fed)</title>
            <description>Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under high calorie breakfast fed.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (T½) of Guaifenesin</title>
          <description>Terminal elimination half-life, calculated from the equation: thalf = In(2)/Kel.</description>
          <population>Pharmacokinetic Dataset</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" spread="2.62"/>
                    <measurement group_id="O2" value="1.07" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Bioavailability (RF) of Guaifenesin</title>
        <description>Relative bioavailability for each formulation will be defined as:
(AUC0-inf Fasting ÷ AUC0-inf Fed) x (Fed dose ÷ Fasting dose)</description>
        <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)</time_frame>
        <population>Outcome involved analyzing data from both intervention groups (Fed and Fasting) in combination as per the provided formula, therefore, separate analysis for each intervention cannot be reported</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
            <description>Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under overnight fasting and fed.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Bioavailability (RF) of Guaifenesin</title>
          <description>Relative bioavailability for each formulation will be defined as:
(AUC0-inf Fasting ÷ AUC0-inf Fed) x (Fed dose ÷ Fasting dose)</description>
          <population>Outcome involved analyzing data from both intervention groups (Fed and Fasting) in combination as per the provided formula, therefore, separate analysis for each intervention cannot be reported</population>
          <units>Percent bioavailability</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0081" spread="0.1655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events(AEs) Experienced by Participants</title>
        <description>Intensity determination Mild=AE does not limit usual activities;subject may experience slight discomfort Moderate=AE results in some limitation of usual activities;subject may experience significant discomfort Severe=AE results in an inability to carry out usual activities;subject may experience intolerable discomfort or pain Unassessable/Unclassifiable=Insufficient information to be able to make an assessment Conditional/Unclassified=Insufficient information to make an assessment at present(causality is conditional on additional information) Unrelated=No possibility that the AE was caused by study drug Unlikely=Slight but remote chance that the AE was caused by study drug but the balance of judgment is that it was most likely not due to the study drug Possible=Reasonable suspicion that the AE was caused by the study drug Probable=Most likely that the AE was caused by study drug Certain=The AE was definitely caused by study drug</description>
        <time_frame>Up to period 2 (8.3 days/200 hours)</time_frame>
        <population>Pharmacokinetic Dataset
Investigational Medicinal Product(IMP)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Mucinex® 600 mg (Fast)</title>
            <description>Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under overnight fasting.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: Mucinex® 600 mg (Fed)</title>
            <description>Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under high calorie breakfast fed.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events(AEs) Experienced by Participants</title>
          <description>Intensity determination Mild=AE does not limit usual activities;subject may experience slight discomfort Moderate=AE results in some limitation of usual activities;subject may experience significant discomfort Severe=AE results in an inability to carry out usual activities;subject may experience intolerable discomfort or pain Unassessable/Unclassifiable=Insufficient information to be able to make an assessment Conditional/Unclassified=Insufficient information to make an assessment at present(causality is conditional on additional information) Unrelated=No possibility that the AE was caused by study drug Unlikely=Slight but remote chance that the AE was caused by study drug but the balance of judgment is that it was most likely not due to the study drug Possible=Reasonable suspicion that the AE was caused by the study drug Probable=Most likely that the AE was caused by study drug Certain=The AE was definitely caused by study drug</description>
          <population>Pharmacokinetic Dataset
Investigational Medicinal Product(IMP)</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE by severity: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE by severity: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE by severity: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP: Unassessable/Unclassifiable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP: Conditional /Unclassified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP: Unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP: Unlikely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP: Possible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP: Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP: Certain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 8.3 days/ (200 hours)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment A: Mucinex® 600 mg (Fast)</title>
          <description>Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under overnight fasting.</description>
        </group>
        <group group_id="E2">
          <title>Treatment B: Mucinex® 600 mg (Fed)</title>
          <description>Single dose Mucinex® 600 mg Extended Release bi-layer tablet by mouth under high calorie breakfast fed.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Vessel puncture site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Director, Clinical Research</name_or_title>
      <organization>Reckitt Benckiser Inc.</organization>
      <email>clinicalrequests@rb.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

